Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Gen-Probe; CardioDx; Scripps Florida, Hanley Center

NEW YORK (GenomeWeb News) – Gen-Probe this week said that it has begun a clinical study of its Progensa PCA3 assay, a molecular test for determining the need for a repeat prostate biopsy. The firm said that the trial would be conducted to support an application to the US Food and Drug Administration for clearance of the assay.

Gen-Probe said that it expects to enroll around 500 men, all of whom have had a negative prostate biopsy, at 10 or more clinical trial sites. It expects the trial to conclude in less than a year, after which it will file the application with FDA.

CardioDx this week said that it had completed a multi-center validation study for its Corus CAD gene expression test for quantifying the likelihood of obstructive coronary artery disease in patients with stable chest pain. The firm said it would publish the result of the study next year. In the meantime, it has made the test available in nine states through its CLIA-certified lab in Palo Alto, Calif., with more states expected to be added in 2010.

A Scripps Florida researcher is collaborating with the West Palm Beach, Fla.-based Hanley Center and the Florida Department of Health on developing a new blood test to predict the risk of relapse in patients with addictions. The researcher, Paul Kenny, will analyze blood samples from patients at the Hanley Center for specific biomarkers that may accurately predict relapse.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.